2009

      03/23/09      Abeille Licenses AB-1001 to Prostrakan For North America, Europe
                              And Other Territories

2007

      03/15/07       Abeille Licenses AB-1001 to Symbio Pharmaceuticals for commercialization
                               in Japan and Pacific RIM countries

2006

      08/09/06       Abeille Submits AB-1001 Phase III Pivotal Efficacy Study Protocol for FDA Review

      05/03/06       Abeille Pharmaceuticals In-Licenses Worldwide Exclusive Rights to
                               Technology for Transdermal Patch Applications

     02/01/06       Abeille initiates Phase I clinical trial of AB-1001 for prevention of Emesis
                               associated with Chemo and Radiation therapy

2005

     11/14/05       Abeille Pharmaceuticals appoints Scientific Advisory Committee

     06/01/05       Abeille Pharmaceuticals appoints two new members to the Board of Directors

Links of Interest:

Specialty Pharma article 1  [LOW-RESOLUTION PDF] ... [HI-RESOLUTION PDF]

Specialty Pharma article 2  [LOW-RESOLUTION PDF]